Technical / White Paper
Challenge of scaleup of High dose-1
The application of oral disintegrating technologies to higher dose actives is a natural extension of this ease of delivery dosage form. A number of companies have marketed products into lower dose therapy < 100 mg using delivery nomenclatures including ODT as well as their own trade mark names. As we enter the next generation of such products, we are seeing more interest in the higher dose 300 mg and higher dosage category of products. Especially in the patient friendly OTC product category
